Carbonate dehydratase

Carbonate dehydratase

The first topical carbonic anhydrase inhibitor for clinical use Dorzolamide HCl (Axon 1517) has been prescribed widely for the treatment of glaucoma and ocular hypertension. It inhibits carbonic anhydrase II (CA-II; EC 4.2.1.1) selectively, which is the main CA iso-enzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed.

Read More
sort-descending
  • Dorzolamide hydrochloride
    1517
    Dorzolamide hydrochloride
    The price depends on the options chosen on the product page

    From $55.00

  • Gallic acid
    2208
    Gallic acid
    The price depends on the options chosen on the product page

    From $55.00

  • CAIX Inhibitor S4
    2662
    CAIX Inhibitor S4
    The price depends on the options chosen on the product page

    From $99.00

  • Brinzolamide
    3988
    Brinzolamide
    The price depends on the options chosen on the product page

    From $77.00

4 Items

More About Carbonate dehydratase

The first topical carbonic anhydrase inhibitor for clinical use Dorzolamide HCl (Axon 1517) has been prescribed widely for the treatment of glaucoma and ocular hypertension. It inhibits carbonic anhydrase II (CA-II; EC 4.2.1.1) selectively, which is the main CA iso-enzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed[1].

[1] Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. J.A. Balfour, M.I. Wilde. Drugs Aging. 1997, 10, 384-403.

Loading...